Consistently, metformin-sensitized lymphoma to isocitrate dehydrogenase (IDH) mutant inhibitors and increased the sensitivity of lymphoma to AZD3965, a monocarboxylate transporter (MCT1) inhibitor, by disturbing mitochondrial complex I and bioenergetics, thus providing a scientific rationale for combinatory mitochondrial-targeted therapies to overcome drug resistance in human lymphoma [53, 258]. Here, IDH3A is linked to lymphoma.